Skip to Main Content
Skip to Footer

Clinical Trial Finder

Blaze a trail to better treatments and a cure for cystic fibrosis.

As a clinical trial volunteer, you are paving the way for new treatments. Search or filter for trials that may be right for you, or learn more about what it means to be a trailblazer.

Share

As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn more about what it means to be a trailblazer.

Showing 1-2 of 2 studies

Remove filter: MS1819-SD

Nutritional-GIEnrolling
OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency , protocol number AzurRX AZ-CF2002

This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).
- Age:
  
  18 Years and Older
- Mutation(s):
  
  No Mutation Requirement
- FEV1% Predicted:
  
  30% or greater
- Number of Visits:
  
  10
- Length of Participation:
  
  8 weeks
Nutritional-GICompleted with Results
OPTION: Study of AzurRx MS1819 in people with cystic fibrosis (CF) and exocrine pancreatic insufficiency who are 18 years and older , protocol number AzurRX AZ-CF2001

This study evaluated the safety and effectiveness of the drug MS1819 as a pancreatic enzyme replacement therapy (PERT). MS1819 is a non-porcine (not pig-derived) lipase-only enzyme for people with CF who have exocrine pancreatic insufficiency (EPI).
- Age:
  
  18 Years and Older
- Mutation(s):
  
  No Mutation Requirement
- FEV1% Predicted:
  
  30% or greater
- Number of Visits:
  
  10
- Length of Participation:
  
  11 weeks

Showing 1-2 of 2 studies

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.

Related Topics

Questions to Ask When Considering a Specific Trial

Clinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.
Patient Safety Is a Priority

Nothing is more important than patient safety in developing new treatments for cystic fibrosis. The U.S. government requires that all clinical trials are supervised for safety, and the Cystic Fibrosis Foundation adds additional measures to protect study volunteers.
Trikafta™

The following is a collection of information and news about Trikafta™, the triple-combination modulator therapy that was approved by the U.S. Food and Drug Administration on Oct. 21, 2019.

Sign up for clinical trial alerts

Get email updates about clinical trials that matter to you.

Email address Please enter a valid email address

Check the Drug Development Pipeline

We’re attacking CF from every angle. Learn about the status of CF drugs in development.

Learn More